Skip to content

Febrile Illness in Guinea

Multidisciplinary Surveillance and Investigation of Febrile Illness in Guinea

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06122259
Acronym
MuSIFe
Enrollment
2500
Registered
2023-11-08
Start date
2023-03-27
Completion date
2026-12-31
Last updated
2023-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Febrile Illness

Brief summary

To date, the underlying causes of community-acquired fever, particularly non-malarial fever, are insufficiently documented in Guinea. Moreover, diagnostic capacity is limited, leading to inadequate prescription of antibiotics and antimalarials, as well as substantial delay in outbreak recognition. Thus, the investigators undertook a prospective observational multi-centric cohort study of febrile patients presenting at the emergency and outpatient department of selected health centers, districts and regional hospitals in four ecologically distinct sentinel health districts in Guinea.

Interventions

None listed

Sponsors

Institute of Tropical Medicine, Belgium
CollaboratorOTHER
Centre National de Formation et de Recherche en Sante Rurale
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Months to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥2 months old * Documented fever (axillary temperature \>37.5°C) at presentation or fever reported within the prior 24 hours * Availability for follow-up for 21 days * Willingness and ability of the patient or culturally acceptable representative to give informed consent for participation in the study

Exclusion criteria

* History of hospitalization (for \> 48 hours within the last 14 days) at any health facility

Design outcomes

Primary

MeasureTime frameDescription
Participants alive (with or without symptoms) or dead at day 21.Day 21Survival or mortality rate will be estimated
Pattern of symptoms and laboratory results at presentation and during follow-upDay 0 and day 21Proportion will be estimated
Syndromic and/or etiologic diagnoses as established at day 21Day 0Proportion will be estimated
Pattern and duration of antibiotic use (and other treatments)Day 0Proportion and mean or median will be estimated
Immediate or secondary hospital admissions and of secondary/unscheduled visitsDay 0 and day 21Proportion will be estimated

Secondary

MeasureTime frameDescription
Association of seasonal, geographical, demographic, clinical and first-line laboratory variables (malaria RDT and smear, biochemistry) with presenting syndromes/main etiologiesDay 0OR or RR will be estimated as appropriate
Confirmed arboviral pathogens and identification of epidemiological/clinical/laboratory predictorsDay 0Proportions will be estimated
Cases fulfilling any of the case definitions of the 20 epidemic-prone infections under surveillance as compared to the final diagnosis and proportion of them timely reported to health authoritiesDay 0Proportions will be estimated
White blood cells and C-reactive protein levels at baseline and association with syndromic/etiologic diagnoses and with patient outcome at day 21Day 0Mean or median level will be estimated

Countries

Guinea

Contacts

Primary ContactKarifa Kourouma, MD, MSc
KKourouma@maferinyah.org+224-628-765-320
Backup ContactAlexandre Delamou, MD, MPH, PhD
adelamou@maferinyah.org+224-628-594-765

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026